These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 27068170)

  • 21. Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
    Otgonsuren M; Estep MJ; Hossain N; Younossi E; Frost S; Henry L; Hunt S; Fang Y; Goodman Z; Younossi ZM
    J Gastroenterol Hepatol; 2014 Dec; 29(12):2006-13. PubMed ID: 25039333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome.
    Yki-Järvinen H
    Lancet Diabetes Endocrinol; 2014 Nov; 2(11):901-10. PubMed ID: 24731669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum fetuin A concentration is elevated in children with non-alcoholic fatty liver disease.
    Lebensztejn DM; Białokoz-Kalinowska I; Kłusek-Oksiuta M; Tarasów E; Wojtkowska M; Kaczmarski M
    Adv Med Sci; 2014 Mar; 59(1):81-4. PubMed ID: 24797980
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidemiology and natural history of non-alcoholic steatohepatitis.
    Argo CK; Caldwell SH
    Clin Liver Dis; 2009 Nov; 13(4):511-31. PubMed ID: 19818302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-alcoholic fatty liver disease: the new epidemic and the need for novel nutritional approaches.
    Selmi C; Bowlus CL; Keen CL; Gershwin ME
    J Med Food; 2007 Dec; 10(4):563-5. PubMed ID: 18158823
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations.
    Preiss D; Sattar N
    Clin Sci (Lond); 2008 Sep; 115(5):141-50. PubMed ID: 18662168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
    Verma S; Jensen D; Hart J; Mohanty SR
    Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The value of different insulin resistance indices in assessment of non-alcoholic fatty liver disease in overweight/obese children.
    El-Karaksy HM; El-Raziky MS; Fouad HM; Anwar GM; El-Mougy FM; El-Koofy NM; El-Hennawy AM
    Diabetes Metab Syndr; 2015; 9(2):114-9. PubMed ID: 25470627
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Awareness and opinions of non-alcoholic fatty liver disease by hospital specialists.
    Bergqvist CJ; Skoien R; Horsfall L; Clouston AD; Jonsson JR; Powell EE
    Intern Med J; 2013 Mar; 43(3):247-53. PubMed ID: 22646061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic disturbances in non-alcoholic fatty liver disease.
    Byrne CD; Olufadi R; Bruce KD; Cagampang FR; Ahmed MH
    Clin Sci (Lond); 2009 Apr; 116(7):539-64. PubMed ID: 19243311
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma Pentraxin 3 Differentiates Nonalcoholic Steatohepatitis (NASH) from Non-NASH.
    Boga S; Koksal AR; Alkim H; Yilmaz Ozguven MB; Bayram M; Ergun M; Sisman G; Tekin Neijmann S; Alkim C
    Metab Syndr Relat Disord; 2015 Nov; 13(9):393-9. PubMed ID: 26367098
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Editorial: Call to screen for NAFLD and NASH in psoriasis.
    Verna EC; Loomba R
    Aliment Pharmacol Ther; 2015 Mar; 41(5):492-3. PubMed ID: 25631653
    [No Abstract]   [Full Text] [Related]  

  • 33. Non-alcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease: Conceptual changes for clinicians, researchers and patients.
    Lin SZ; Chen YW; Fan JG
    J Dig Dis; 2020 Nov; 21(11):604-609. PubMed ID: 32975050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of non-alcoholic fatty liver disease.
    Dyson J; Day C
    Dig Dis; 2014; 32(5):597-604. PubMed ID: 25034293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Update on non-alcoholic fatty liver disease in children.
    Papandreou D; Rousso I; Mavromichalis I
    Clin Nutr; 2007 Aug; 26(4):409-15. PubMed ID: 17449148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characteristics and diagnosis of NAFLD/NASH.
    Hashimoto E; Taniai M; Tokushige K
    J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():64-70. PubMed ID: 24251707
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-alcoholic fatty liver disease.
    Tuyama AC; Chang CY
    J Diabetes; 2012 Sep; 4(3):266-80. PubMed ID: 22564417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches.
    Schuppan D; Schattenberg JM
    J Gastroenterol Hepatol; 2013 Aug; 28 Suppl 1():68-76. PubMed ID: 23855299
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD).
    Ali R; Cusi K
    Ann Med; 2009; 41(4):265-78. PubMed ID: 19353360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidemiology of non-alcoholic fatty liver disease.
    Bellentani S; Scaglioni F; Marino M; Bedogni G
    Dig Dis; 2010; 28(1):155-61. PubMed ID: 20460905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.